The Latest Breaking News from Arcellx

Arcellx shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

After a red letter day on the stock market, investor enthusiasm kept climbing on the Dow Jones index as all major indexes piled on gains.

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Upgrades